Pharma Tech

Lilly-backed Oyster Therapeutics raises $60m for neurological degraders

Nov 11, 2026, 9:39 AM

Read Full Article → Lilly-backed Oyster Therapeutics raises $60m for neurological degraders

Translate article text

Choose a language and wait for the translated text.

Oyster Therapeutics has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.